- Targets solid waste, wastewater, industrial odor, advanced wound-care and distinfectant markets
- Clyra Medical unit has applied its technology to the coronavirus pandemic with public sales of its disinfectant spray
- Flagship product CupriDyne Clean marketed to cannabis producers seeking odor elimination
- Working with US EPA to develop system to remove harmful ‘forever chemicals’ from drinking water
What BioLargo does:
Inc () is an environmental engineering company with a simple mission: “To make life better” when it comes to clean water, clean air and good health.
The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care.
BioLargo operates four subsidiaries: Odor-No-More Inc, BioLargo Water Inc, BioLargo Engineering, Science & Technologies Inc (BLEST) and Clyra Medical Technologies Inc.
The Odor-No-More division’s main product is CupriDyne Clean Industrial Odor and VOC Eliminator, which is aimed at the solid waste/landfill/compost, wastewater, and oil & gas industries. The product eliminates odor-causing compounds rather than masking them.
The BioLargo Water division develops the Advanced Oxidation System (AOS), an industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than current technologies.
The BioLargo Engineering division piggybacks on BioLargo Water by offering consulting and engineering services for the water and wastewater treatment industries. It also conducts environmental and Occupational Safety and Health Administration workplace-safety compliance audits.
The engineering division, along with the Odor-No-More unit, is targeting cannabis companies to adopt the company’s CupriDyne Clean product, which eliminates the strong, pungent odors and VOCs emitted during growing and production. BioLargo cites some 15,000 cannabis production sites in California as potential customers.
The Clyra Medical unit – in which BioLargo owns a minority 45% interest via a subsidiary – develops medical products to safely treat chronic wound infections and promote healing while reducing the need for antibiotic based on BioLargo’s technologies through a license agreement calling for 6% royalty payments.
Clyra is advancing with its stem-therapy technology called SkinDisc that uses a patient’s own bone marrow and plasma to help heal chronic wounds. The division also has US Food and Drug Administration clearance to market its Clyra Wound Irrigation Solution product for cleansing, irrigating, and debriding dermal wounds and burns.
The subsidiary has also taken its wound-healing technology and applied it to the coronavirus (COVID-19) pandemic in the form disinfectant products, including Clyraguard…